Collegium Pharmaceutical Inc (COLL)
33.55
+0.09
(+0.27%)
USD |
NASDAQ |
Nov 04, 13:04
Collegium Pharmaceutical Enterprise Value: 1.359B for Nov. 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 01, 2024 | 1.359B |
| October 31, 2024 | 1.381B |
| October 30, 2024 | 1.398B |
| October 29, 2024 | 1.416B |
| October 28, 2024 | 1.413B |
| October 25, 2024 | 1.399B |
| October 24, 2024 | 1.386B |
| October 23, 2024 | 1.437B |
| October 22, 2024 | 1.447B |
| October 21, 2024 | 1.456B |
| October 18, 2024 | 1.519B |
| October 17, 2024 | 1.535B |
| October 16, 2024 | 1.548B |
| October 15, 2024 | 1.522B |
| October 14, 2024 | 1.505B |
| October 11, 2024 | 1.496B |
| October 10, 2024 | 1.462B |
| October 09, 2024 | 1.491B |
| October 08, 2024 | 1.506B |
| October 07, 2024 | 1.563B |
| October 04, 2024 | 1.630B |
| October 03, 2024 | 1.566B |
| October 02, 2024 | 1.544B |
| October 01, 2024 | 1.560B |
| September 30, 2024 | 1.526B |
| Date | Value |
|---|---|
| September 27, 2024 | 1.514B |
| September 26, 2024 | 1.520B |
| September 25, 2024 | 1.486B |
| September 24, 2024 | 1.499B |
| September 23, 2024 | 1.512B |
| September 20, 2024 | 1.540B |
| September 19, 2024 | 1.535B |
| September 18, 2024 | 1.530B |
| September 17, 2024 | 1.485B |
| September 16, 2024 | 1.477B |
| September 13, 2024 | 1.489B |
| September 12, 2024 | 1.458B |
| September 11, 2024 | 1.447B |
| September 10, 2024 | 1.443B |
| September 09, 2024 | 1.463B |
| September 06, 2024 | 1.479B |
| September 05, 2024 | 1.493B |
| September 04, 2024 | 1.513B |
| September 03, 2024 | 1.487B |
| August 30, 2024 | 1.520B |
| August 29, 2024 | 1.525B |
| August 28, 2024 | 1.476B |
| August 27, 2024 | 1.499B |
| August 26, 2024 | 1.491B |
| August 23, 2024 | 1.449B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
306.93M
Minimum
Nov 04 2019
1.695B
Maximum
Mar 27 2024
1.059B
Average
1.154B
Median
May 10 2022
Enterprise Value Benchmarks
| Rigel Pharmaceuticals Inc | 260.44M |
| Esperion Therapeutics Inc | 471.51M |
| Context Therapeutics Inc | 68.71M |
| NovaBay Pharmaceuticals Inc | 3.615M |
| Palatin Technologies Inc | 13.93M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 19.61M |
| Revenue (Quarterly) | 145.28M |
| Total Expenses (Quarterly) | 97.80M |
| EPS Diluted (Quarterly) | 0.52 |
| Gross Profit Margin (Quarterly) | 62.51% |
| Profit Margin (Quarterly) | 13.50% |
| Earnings Yield | 7.72% |
| Operating Earnings Yield | 13.08% |
| Normalized Earnings Yield | 8.077 |